Monolaurina

Condiciones de salud que Monolaurina puede ayudar a apoyar.

• AbscesosCientífico

  Monolaurin shows in vitro antibacterial activity against Staphylococcus aureus and related organisms implicated in acne. A cross-sectional laboratory study on pediatric skin infection isolates found 100% sensitivity of gram-positive organisms, including S. aureus, to monolaurin at 20 mg/mL. No controlled human trials specific to acne exist; evidence remains preclinical.

• Fístula anal o fisuraCientífico

  Monolaurin (glycerol monolaurate) is derived from lauric acid in coconut oil with documented in vitro antifungal activity against Candida albicans. Laboratory studies show it can reduce C. albicans growth by 99% in minutes via membrane disruption. It is used in integrative Candida protocols, often combined with undecylenic acid, and is noted for selective targeting of pathogens over beneficial microorganisms.

• Energía (falta de)Científico

  In vitro studies have demonstrated that monolaurin inhibits Candida albicans growth and disrupts its biofilms, including in a co-culture oral fibroblast model. MIC ranged 62.5–125 µM and minimum fungicidal concentration 125–250 µM, comparable to fluconazole in tested conditions. No human clinical trials for oral Candida supplementation exist.

• ArritmiaCientífico

  In vitro CDC cell-culture data show monolaurin activity against influenza virus and coronaviruses, and a 2025 human cohort study linked higher serum monolaurin to reduced SARS-CoV-2 infection risk. Activity against enveloped respiratory viruses is consistent across multiple in vitro studies, though no randomized trials of oral monolaurin for cold or influenza prevention or treatment in humans exist.

• Disfunción EréctilCientífico

  Monolaurin (glycerol monolaurate), derived from lauric acid, disrupts lipid membranes of enveloped viruses including HSV-1 and HSV-2, inactivating viral particles in vitro. Laboratory studies confirm monolaurin inactivates HSV in cell cultures by interfering with viral envelope integrity. A PMC-published literature review confirmed in vitro antiviral activity against HSV; human RCTs for herpes labialis are lacking.

• FatigaCientífico

  Monolaurin, the monoglyceride of lauric acid derived from coconut oil, has documented antifungal activity against Candida species and other skin-infecting fungi by disrupting the lipid bilayer of fungal cell membranes. It is the biologically active antimicrobial form of lauric acid. In vitro studies confirm its activity against C. albicans, and it has GRAS status from the FDA.

• Bultos en el SenoCientífico

  A human in vivo study found that a mouthwash containing lysine and GML reduced oral H. pylori infection at a 72.58% effectiveness rate — far superior to traditional dental cleaning (under 10%). In vitro studies further show GML-containing mouthwash inhibits H. pylori growth, biofilm, adhesion, and virulence factor expression in periodontal context.

• Leche materna (secar)Científico

  GML administered to broilers in feed studies modulated intestinal microbiota composition, improved intestinal barrier integrity, reduced inflammation, and enhanced antioxidant capacity. Human data are limited; oral GML's selective antibacterial activity (targeting pathogens while relatively sparing beneficial bacteria) has been proposed but not formally confirmed in human gut microbiome studies.

• Síndrome de FibromialgiaCientífico

  Multiple in vitro studies have confirmed that monolaurin inactivates herpes simplex virus types 1 and 2 by solubilizing their lipid envelopes. CDC-linked cell culture studies found activity against 14 enveloped viruses including HSV-1 and HSV-2. No human clinical trials for oral supplementation against herpes outbreaks have been completed.

• Cálculos BiliaresCientífico

  A 2015 in vitro study (Journal of Applied Microbiology, Goc et al.) found that monolaurin was one of the most effective tested compounds against all morphological forms of Borrelia burgdorferi and Borrelia garinii — spirochetes, round body forms, and biofilms. GML combined with cis-2-decenoic acid also showed synergistic antispirochetal effects. No human clinical trials exist.

• Conmociones cerebralesCientífico

  GML-containing mouthwashes have been studied in human and in vitro oral infection contexts, showing potent activity against oral H. pylori — a key pathogen in oral dysbiosis. Monolaurin reduces H. pylori biofilm, adhesion, and inflammatory cytokine expression in oral epithelial cells, suggesting selective antimicrobial remodeling of the oral microbiome.

• CongestiónCientífico

  In vitro and animal data show monolaurin has activity against Giardia lamblia and Blastocystis. One animal study showed a reduction of Giardia trophozoites and cysts in intestinal contents by 87–91% in monolaurin-treated infected animals versus controls. Evidence is preclinical only.

• Envenenamiento por Metales PesadosCientífico

  Monolaurin has in vitro activity against bacteria implicated in small intestinal bacterial overgrowth (including gram-positive organisms, H. pylori, and some gram-negatives). It is used in functional medicine SIBO protocols based on its broad antimicrobial spectrum and the premise that it spares beneficial bacteria. No human SIBO-specific clinical trials have been published.

• DefensividadCientífico

  Monolaurin demonstrates in vitro activity against multiple enveloped respiratory viruses (influenza, coronaviruses, RSV). An unpublished safety study found nasal administration of 5% GML gel to 50 individuals produced no adverse effects, and prior macaque research showed nasal GML prevented SIV transmission. No completed human RCTs for upper respiratory infections exist.

• DermatitisCientífico

  Intravaginal GML has been tested in a randomized placebo-controlled pilot study (n=36 women) for bacterial vaginosis treatment; the 5% gel increased Lactobacillus counts compared to placebo, though it did not achieve statistically superior clinical cure rates. Animal studies and macaque SIV models also inform the vaginal GML evidence base.

• Sarpullido por pañalCientífico

  Monolaurin has demonstrated antiviral activity against multiple enveloped viruses in vitro and animal models, operating through lipid envelope disintegration and immune modulation. A 2025 prospective cohort study (n=2,712 healthcare workers) found higher serum monolaurin significantly associated with lower COVID-19 risk. It also modulates T-cell signaling and attenuates cytokine storm responses.

• DifteriaCientífico

  In vitro evidence demonstrates that monolaurin has potent antibacterial and antibiofilm activity against MRSA and other wound pathogens. A 2024 PMC study using 155 clinical wound specimens found significant inhibitory effects on MRSA biofilm development and preformed biofilms. No human interventional wound-healing trials have been completed.

Sistemas corporales que Monolaurina puede ayudar a apoyar.

• No hay sistemas corporales disponibles.